P

Prostate Cancer Centre | Calgary, Canada

Research site
(Unclaimed)
Location
7007 14 Street SW, Suite 6500, Calgary, Alberta, Canada

Site insights

Top conditions

Top treatments

Darolutamide
Enzalutamide
Apalutamide
Abiraterone Acetate
Prednisone
Leuprolide
BAY1841788
Talazoparib
Androgen
Niraparib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 14 total trials

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Placebo for Niraparib
Drug: Niraparib

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC.Phase 1 of the study will be a sing...

Enrolling
Prostate Cancer
Drug: Enzalutamide
Drug: EPI-7386 with Enzalutamide

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radica...

Active, not recruiting
Hormone Sensitive Prostate Cancer
Prostate Cancer
Drug: Enzalutamide
Drug: Placebo (No longer applicable in Open Label study period)

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

Trial sponsors

J
Bayer logo
Pfizer logo
E
E
E
J
N
A
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems